Risarestat

Risarestat (CT-112), an aldose reductase inhibitor, is developed for the treatment of diabetic complications.

Product Specifications

CAS Number

[79714-31-1]

Product Name Alternative

CT 112

UNSPSC

12352005

Target

Aldose Reductase

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Metabolic Disease; Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/RISARESTAT.html

Purity

98.03

Solubility

DMSO : 105 mg/mL (ultrasonic)

Smiles

O=C(N1)SC(C2=CC=C(OCCCCC)C(OCC)=C2)C1=O

Molecular Formula

C16H21NO4S

Molecular Weight

323.41

References & Citations

[1]Awata T, et al. Effect of an aldose reductase inhibitor, CT-112, on healing of the corneal epithelium in galactose-fed rats. J Ocul Pharmacol. 1988 Fall;4 (3) :195-201.|[2]Ohashi Y, et al. Intraocular penetration of CT-112, an aldose reductase inhibitor, following topical instillation. J Ocul Pharmacol. 1989 Winter;5 (4) :325-8.|[3]Hosotani H, et al. Reversal of abnormal corneal epithelial cell morphologic characteristics and reduced corneal sensitivity in diabetic patients by aldose reductase inhibitor, CT-112. Am J Ophthalmol. 1995 Mar;119 (3) :288-94.|[4]Jacot JL, et al. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. J Ocul Pharmacol Ther. 1998 Apr;14 (2) :169-80.